Kong T. Nguyen

Proteorex Therapeutics, Inc. develops novel therapeutics. It is discovering small-molecule drugs to treat diseases with the greatest unmet medical need. The firm’s drug discovery platform integrates a novel synthesis design strategy, machine learning, and patient-derived cell-based screening to unlock targets considered undruggable using existing approaches. The company was founded by Aman Iqbal, Kong T. Nguyen, Robert Batey and Michael Anstey and is headquartered in Toronto, Canada.

Proteorex Therapeutics, Inc. develops novel therapeutics. It is discovering small-molecule drugs to treat diseases with the greatest unmet medical need. The firm’s drug discovery platform integrates a novel synthesis design strategy, machine learning, and patient-derived cell-based screening to unlock targets considered undruggable using existing approaches. The company was founded by Aman Iqbal, Kong T. Nguyen, Robert Batey and Michael Anstey and is headquartered in Toronto, Canada.